Biotech Business - January 18, 2017
Pelago Bioscience and CBCS collaborates
Pelago Bioscience and Chemical Biology Consortium Sweden (CBCS), the chemical biology facility at Karolinska Institutet and SciLifeLab (Science for Life Laboratory) will collaborate to develop high throughput automated CETSA-based Target Engagement Assays for multiple targets. The collaboration is based on expanding Pelago’s CETSA technology capabilities and will enable screening of large chemical libraries for identification […]
Biotech Business - January 13, 2017
Pelago collaborates with Sygnature
UK’s Sygnature Discovery will collaborate with Swedish biotech company Pelago Bioscience to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA) method. Pelago’s CETSA method enables measurements to be made within cellular systems. For the first time researchers can now measure directly how a compound interacts with its target within the cell […]
Agreement - November 27, 2015
Pelago Bioscience, AstraZeneca enter agreement
Pelago Bioscience AB and AstraZeneca have entered into a 2-year strategic research collaboration and license agreement. The companies will collaborate on specified joint projects and AstraZeneca will also be granted a license to use and apply the Cellular Thermal Shift Assay (CETSA®) for determination and quantification of drug–target interactions in other AstraZeneca discovery projects. During the […]
Drug Development Pharma - July 2, 2014
Pelago Bioscience enters agreement with GSK
Pelago Bioscience AB has entered a method licensing agreement with GlaxoSmithKline. The agreement regards the use of the Cellular Thermal Shift Assay for determination and quantification of drug–target interactions. Under the agreement, Pelago Bioscience grants GSK a license to the CETSA method for use in research & development. Pelago Bioscience was spun out from the […]
